Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
IQVIA is a global leader in providing data-driven insights, advanced analytics, technology solutions, and clinical research services to the biopharmaceutical and healthcare industries. Operating in the healthcare sector, IQVIA assists its clients, including pharmaceutical, biotechnology, and medical device companies, in optimizing their research and development processes, improving commercial effectiveness, and navigating the complexities of the healthcare landscape. With a strong emphasis on leveraging its extensive data assets and advanced analytics capabilities, IQVIA holds a leading market position in the global life sciences consulting and services space, enabling its clients to accelerate innovation and improve patient outcomes.
Department | HeadCount |
---|---|
Administrative | 2158 |
Consulting | 2632 |
Service | 877 |
Design | 148 |
Education | 329 |
Finance | 854 |
Management | 486 |
Hr | 868 |
Legal | 902 |
Marketing | 561 |
Medical | 5255 |
Operations | 3895 |
Department | 9728 |
Product | 541 |
Management | 3531 |
Estate | 6 |
Research | 8968 |
Sales | 1738 |
Technical | 5467 |
Trades | 24 |
IQVIA's department distribution reflects a business model centered around data, research, and technology services, typical of a life sciences focused company. The substantial "Other Department" headcount, along with significant numbers in "Research," "Medical," and "Technical" roles, underscores its commitment to scientific rigor, clinical expertise, and technological innovation. The robust "Project Management" division highlights the importance of efficiently delivering complex projects to pharmaceutical clients. The presence of a "Consulting" department further indicates a strategic focus on advisory services to help clients navigate the complex regulatory, market access, and commercial landscapes. While a "Sales" department exists, its size relative to research and technical roles suggests that IQVIA's growth is primarily driven by its core service offerings and established client relationships. Lower numbers in traditional support functions like "Finance," "HR," and "Marketing" imply a centralized and efficient operational model. This structure aligns well with IQVIA's strategy of providing integrated, end-to-end solutions to the life sciences industry, emphasizing data-driven insights and technological advancements.
Total: 48,907 employees
IQVIA possesses a globally distributed workforce strategically positioned to serve the international biopharmaceutical market. Its largest employee concentrations in India and the United States reflect a dual focus on leveraging cost-effective operational hubs (India) and maintaining a strong presence in major pharmaceutical markets and corporate headquarters locations (United States). A significant footprint in European countries such as the United Kingdom, Spain, Germany, France, and Italy demonstrates a commitment to serving the established European pharmaceutical sector. The substantial presence in Brazil and Argentina underlines the importance of the Latin American market to IQVIA's global strategy. Furthermore, the company's presence in numerous smaller countries across various continents illustrates a dedication to global coverage and the ability to support clinical trials and provide consulting services worldwide. The smaller employee numbers in African countries signify an emerging market focus and investment in regional research capabilities. Overall, IQVIA's geographic distribution aligns with its global business model of offering clinical research, commercial services, and advanced analytics to pharmaceutical companies, positioning it as a key partner in both established and developing pharmaceutical markets.
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early